Fabien XUEREB PharmD, PhD, Clinical Pharmacy and Pharmacokinetics

Course and current status

I did my pharmacy studies in Limoges (France) and moved to Bordeaux in November 2001 for my internship (Hospital University of Bordeaux and University of Bordeaux II, France). I chose to specialize in Hospital Pharmacy (Clinical Pharmacy and Pharmacokinetics). Between 2004 and 2008, I performed research at the European Institute of Chemistry and Biology (IECB) & University of Bordeaux I (France), with Pr Jean-Marie Schmitter (Master's degree & PhD). Between 2009 and 2012, I held the position of University and hospital Assistant Pharmacist (University of Bordeaux Segalen and Bordeaux Hospital University Center).

I am now Assistant Professor Researcher & Hospital Pharmacist since september 2012. I'm the head of the clinical pharmacy and medicine dispensing sector of the University Hospital of Bordeaux, teacher in Clinical Pharmacy & Pharmacokinetics at the school of Pharmaceutical Sciences (University of Bordeaux, France), and Researcher at INSERM U1034 Biology of Cardiovascular Diseases (Pessac, France), team 1 “Hedgehog and vessel disease”, project "Cerebrovascular disease and blood-brain barrier".

I am Member of French Society of Clinical Pharmacy (SFPC) since February 2009, Member of French Clinical Pharmacy Teachers Association (ANEPC) since July 2016, Member of French Pharmacokinetics Teachers Association (GEPK) since January 2015. 

University degrees :

PhD, Chemical Sciences, Analytical Chemistry and Environment, European Institute of Chemistry and Biology (IECB) & University of Bordeaux I (France), Mass spectrometry of biological macromolecules (2004 - 2008)

Diploma of Specialized Studies (DES) in Hospital Pharmacy (Internship), School of Pharmaceutical Sciences, University of Bordeaux II (France) (2001 - 2006)

Master's degree (M2R) Biology and Health, Structural Biochemistry, European Institute of Chemistry and Biology (IECB) & Universities Bordeaux I & II (2003 - 2004)

Inter-University Diploma (DIU) in Statistics Applied to Medicine (CESAM), School of Medical Sciences, Pierre and Marie Curie University (Paris VI) (France), Statistical Methodology and Practice of Clinical Trials (2002 - 2003)

Doctor of Pharmacy (PharmD), Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of Limoges (France) (1995 - 2001)

Scientific summary

My first research theme focused on the development of an analytical strategies for quantifying therapeutic proteins in human plasma in order to carry out therapeutic drug monitoring and optimization of treatments, the main objective being the patient management in terms of efficacy and safety. My first work (2004-2008) focused on the development of an analytical strategy for quantifying erythropoietin beta (Ph.D. University argued in 2008, in collaboration with the mass spectrometry team Pr JM Schmitter (IECB, Pessac) (J Clin Pharm. 2008 27 (3): 181-8), Int J Pharm 2010; 396: 140-142, Anal Chem Bioanal 2011, 400: 2073-2084). The knowledge acquired by the team in the field of therapeutic proteins then led us to focus on therapeutic monoclonal antibodies, and my following work focuses on the  implementation of the quantification strategy developed on bevacizumab, a widely used monoclonal anti-angiogenic antibody, in view of pharmacokinetics and pharmacokinetic / pharmacodynamic study for dose optimization in cancer patients, based on the monitoring of plasma concentrations, to search effective concentrations and concentrations causing toxic effects (bleeding and thromboembolism) (Co-supervision of R Legeron' PhD (2011-2015), collaboration with the mass spectrometry team Pr JM Schmitter, PGF, Bordeaux (J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1070:43-53)).

Since 2015, my main research work is focused on understanding the modulation of vascular functions by drugs inhibitors of Hedgehog (Hh) signaling pathway in mouse models according to various dosing regimen: relationship between the pharmacokinetics (PK) parameters of vismodegib, and pharmacodynamics (PD) parameters (blood pressure, neuropathies, dysgeusia, histology, Gli1 expression) with the aim of developing PK/PD modeling and further optimizing drug regimens and efficacy-toxicity balance in humans. Since 2018, our team has implemented a clinical research project (OPTIVISMO-1, Bordeaux University Hospital is the sponsor) and which studies the relationship between the pharmacokinetics of vismodegib and tolerance data in patients with of  basal cell carcinoma. 

In addition, I am involved since 2002 in other research topics of the team on pharmacokinetics / pharmacodynamics correlations of anti-infective therapeutics (carbapenems, amoxicillin / clavulanic acid, piperacillin / tazobactam, moxifloxacin, linezolid, tobramycin, ceftriaxone, azole antifungals, antiretrovirals) and immunosuppressants.

Image d’exemple